Kyowa Kirin Co., Ltd.

This early-stage trial is testing a new drug called KK3910 in healthy people and those with high blood pressure. The main goal is to check safety and how the drug moves through the body. It is a small, placebo-controlled study, so it is too soon to know if the drug actually works…

This early-stage study tests a new drug called KK2845 for adults whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The goal is to find a safe dose and see how well the body tolerates it. About 72 participants will take part in two phases: …

This study is the first time the experimental drug KK2430 is being tested in humans. It aims to find out if KK2430 is safe, how the body processes it, and whether it can help treat blood cancers. About 72 adults with blood cancers that have not responded to other treatments will …

This study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how…

This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. Ab…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This study tests a new drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare genetic condition that causes low phosphate levels and bone problems. The trial has two parts: first, finding the right dose, then checking safety and how well it works over time. Ab…

This study is tracking how safe and effective the drug mogamulizumab (Poteligeo) is for adults with two rare types of skin lymphoma: mycosis fungoides and Sézary syndrome. Researchers will monitor 15 participants in routine care settings for side effects and how well the drug con…